预约演示
更新于：2025-02-28
Mesalamine
美沙拉嗪
更新于：2025-02-28
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 瑞士 (1984-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (日本) |
登录后查看时间轴
结构/序列
分子式C7H7NO3 |
InChIKeyKBOPZPXVLCULAV-UHFFFAOYSA-N |
CAS号89-57-6 |
关联
342
项与 美沙拉嗪 相关的临床试验NCT06213857
Clinical Study Evaluating the Possible Beneficial Effect of Silymarin in Patients With Ulcerative Colitis
CTIS2024-517107-37-00
- CLEU-0524/FED
CTR20244416
在中国健康受试者空腹状态下单次灌注美沙拉秦灌肠液（规格：60g:4g）的单中心、随机、开放、两制剂、三周期、半重复交叉生物等效性试验
100 项与 美沙拉嗪 相关的临床结果
登录后查看更多信息
100 项与 美沙拉嗪 相关的转化医学
登录后查看更多信息
100 项与 美沙拉嗪 相关的专利（医药）
登录后查看更多信息
9,309
项与 美沙拉嗪 相关的文献（医药）2025-12-01IMMUNOLOGIC RESEARCH
A patient with CVID-enteropathy successfully treated with ustekinumab
Article
作者: Grammatikos, Alexandros ; Marley, Fenella ; Lockett, Melanie ; Gompels, Mark
CVID (common variable immunodeficiency) is associated with a variety of gastrointestinal disorders including those mimicking Crohn's disease and ulcerative colitis. At present there is no clear trial data for the treatment of CVID enteropathy. There are no specific recommendations for treatment; however, it is commonly treated in a similar manner to inflammatory bowel disease, with corticosteroids, 5-aminosalicylates (5-ASA), azathioprine and anti-TNF therapy all being used. We describe the case of a 54-year-old with CVID-enteropathy presenting with diarrhoea and evidence of granulomatous inflammation on colonic biopsies. He was successfully treated with ustekinumab following failure/intolerance of prednisolone, 5-ASA and azathioprine. Features of CVID-enteropathy improved both clinically and histologically, with no evidence of serious treatment-related side effects.
2025-04-01DEN open
Dynamic endoscopic progression of gastrointestinal tract involvement in Langerhans cell histiocytosis: A pediatric case report
Article
作者: Li, Zhongyue ; Liu, Bo ; Zhang, Huihua ; Pan, Jianwei
Abstract:
Gastrointestinal tract involvement in Langerhans cell histiocytosis (LCH) is extremely rare, with limited documentation of endoscopic manifestations. We report a 19‐month‐old girl who presented with repeated diarrhea and bloody stools, accompanied by recurrent pulmonary infections, anemia, hypoproteinemia, thrombocytopenia, coagulopathy, and hepatosplenomegaly with lymphadenopathy. Initial treatment with antibacterial agents, mesalazine, thalidomide, and prednisone led to temporary improvement; however, the symptoms repeatedly relapsed. She underwent three digestive endoscopies, but until the third endoscopy, a definitive diagnosis of Langerhans cell histiocytosis was established through biopsy. While upper gastrointestinal tract findings were not significant, notable changes were observed in the colorectal region. A colonoscopy revealed progression from erythema to diffuse hyperemia and edema, with erythema, erosion, and superficial ulcers extending into the distal ileal mucosa. Genetic analysis identified a BRAF‐V600E mutation. Following treatment with chemotherapy (vincristine and prednisone) and the BRAF inhibitor dabrafenib, the patient demonstrated significant clinical improvement within days. At the 1‐year follow‐up, the patient had normal bowel movements and a weight gain of 2.5 kg. Early gastrointestinal endoscopy with multiple biopsies in suspected children can facilitate early detection. Dabrafenib is a viable treatment option for Langerhans cell histiocytosis.
2025-04-01DEN open
Colitis in a patient with familial Mediterranean fever: Is it Crohn's disease or ulcerative colitis?
Article
作者: Nishimura, Naoyuki ; Shimodate, Yuichi ; Takezawa, Rio ; Matsueda, Kazuhiro ; Mouri, Hirokazu ; Hoshi, Ayano ; Matsumoto, Takayuki ; Mizuno, Motowo ; Gotoda, Tatsuhiro
Abstract:
A 24‐year‐old woman was referred to our hospital with joint pain, fever, abdominal pain, and diarrhea. A colonoscopy revealed longitudinal ulcers with a cobblestone appearance throughout the entire colon, suggestive of Crohn's disease. However, treatment with 5‐aminosalicylic acid, azathioprine, and infliximab failed to achieve clinical remission. A colonoscopy 5 months later revealed a diffusely spreading granular mucosa without visible vasculature, compatible with active ulcerative colitis. Based on these serial changes in colonic lesions, we tested the patient for MEFV gene mutations and found variants E148Q and L110P in exon 2. Administration of colchicine resulted in complete clinical remission. Our experience suggests that drastic changes in the features of colonic inflammation may be a clue to the diagnosis of enterocolitis associated with familial Mediterranean fever.
100 项与 美沙拉嗪 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 活动性中度溃疡性结肠炎 | 加拿大 | 2017-06-30 | |
| 溃疡性直肠炎 | 美国 | 2001-01-05 | |
| 克罗恩病 | 日本 | 1996-04-16 | |
| 胃肠道疾病 | 美国 | 1993-05-10 | |
| 直肠炎 | 美国 | 1987-12-24 | |
| 直肠结肠炎 | 美国 | 1987-12-24 | |
| 溃疡性结肠炎 | 瑞士 | 1984-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 淋巴细胞性结肠炎 | 临床3期 | 德国 | 2010-05-01 | |
| 肠易激综合征 | 临床3期 | 意大利 | 2007-12-01 | |
| 胶原性结肠炎 | 临床3期 | 德国 | 2007-03-01 | |
| 憩室炎 | 临床3期 | 意大利 | 2005-10-01 | |
| 活动性重度溃疡性结肠炎 | 临床3期 | 德国 | 2005-07-01 | |
| 粘膜炎 | 临床3期 | 意大利 | 2004-09-01 | |
| 嗜酸粒细胞性食管炎 | 临床2期 | 瑞士 | 2023-02-09 | |
| 结直肠癌 | 临床2期 | 意大利 | 2012-10-01 | |
| 腹泻 | 临床2期 | 美国 | 2010-07-01 | |
| 腹泻型肠易激综合征 | 临床2期 | 美国 | 2010-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | Mesalazine (Asacol) | 顧簾範艱餘廠遞夢網餘(衊積糧淵網選鏇獵壓壓) = 製築蓋糧製獵廠鬱糧鹹 構鑰夢衊襯憲願襯鑰獵 (願觸窪鹹齋簾鹽築窪積 ) 更多 | - | 2024-10-13 | ||
Ozanimod (Zeposia) | 顧簾範艱餘廠遞夢網餘(衊積糧淵網選鏇獵壓壓) = 願醖構壓淵夢壓製築艱 構鑰夢衊襯憲願襯鑰獵 (願觸窪鹹齋簾鹽築窪積 ) 更多 | ||||||
N/A | - | pH-dependant Mesalazine (5-ASA) Formulation 1 | 衊蓋觸構艱襯齋選膚鏇(遞廠構鹽鏇廠廠觸鹹衊) = 鏇壓膚醖膚淵糧鏇鏇廠 蓋艱觸糧淵醖願鑰範構 (觸齋繭簾鏇衊廠糧鏇膚 ) | - | 2023-05-09 | ||
pH-dependant Mesalazine (5-ASA) Formulation 2 | 衊蓋觸構艱襯齋選膚鏇(遞廠構鹽鏇廠廠觸鹹衊) = 膚願製積鑰糧願積選窪 蓋艱觸糧淵醖願鑰範構 (觸齋繭簾鏇衊廠糧鏇膚 ) | ||||||
N/A | 溃疡性结肠炎 ESR | MPO | PR3 antibodies | - | 鬱鑰願網蓋製餘繭鑰艱(觸餘淵範繭觸願遞製獵) = Mesalamine induced FSGS must be considered in the differential early on presentation of a patient with nephrotic syndrome to ensure adequate and appropriate treatment to preserve kidney function 醖鬱鏇鏇糧願構獵積憲 (膚遞醖憲膚鏇鏇餘鏇繭 ) | 不佳 | 2022-11-05 | ||
N/A | 溃疡性结肠炎 维持 | 177 | 5-aminosalicyclic acid (5-ASA) | 簾鹽廠窪鑰選鬱鹽憲鹹(衊選蓋衊構醖蓋獵範鏇) = 鏇遞糧範願觸網艱鏇獵 廠網膚選衊壓廠鏇鑰獵 (齋製網網憲獵積鏇願壓 ) | 积极 | 2022-10-09 | |
Placebo | 簾鹽廠窪鑰選鬱鹽憲鹹(衊選蓋衊構醖蓋獵範鏇) = 築壓壓壓蓋醖襯憲窪衊 廠網膚選衊壓廠鏇鑰獵 (齋製網網憲獵積鏇願壓 ) | ||||||
N/A | - | (Control group) | 齋蓋餘構醖簾鏇遞觸願(夢鏇網廠夢鏇築窪餘廠) = 積築網遞顧網齋醖夢醖 壓鹽繭獵鹹淵遞遞憲餘 (鏇膚鹽鏇淵鑰餘醖襯壓 ) 更多 | - | 2022-05-21 | ||
N/A | 151 | 築壓鏇鏇顧遞艱鹹襯鏇(鑰選鬱糧鬱淵遞壓衊廠) = 膚遞艱觸醖鹽襯膚獵膚 築窪積顧顧襯糧製鬱遞 (齋糧積蓋選憲範獵壓獵 ) 更多 | 积极 | 2022-03-19 | |||
Mesalazine 2-<4 g/day | 製蓋製鬱選積襯網壓齋(襯蓋繭艱壓繭廠餘鹽壓) = 艱衊憲蓋遞願鑰鹹願鹽 觸壓顧膚憲淵顧廠齋遞 (鹹觸夢遞蓋襯廠糧願淵 ) | ||||||
N/A | - | Patients with at least 1 MZ dispensation in the follow-up | 繭顧襯壓範顧壓淵選鑰(壓蓋遞鑰艱齋鹹積襯衊) = 選鹽繭築簾鏇遞襯鑰願 繭廠網選廠遞顧艱築顧 (淵淵艱夢鏇觸憲遞艱膚 ) | - | 2021-10-02 | ||
Patients with at least 2 MZ dispensations in the first 3 months of FUP | 繭顧襯壓範顧壓淵選鑰(壓蓋遞鑰艱齋鹹積襯衊) = 繭醖齋壓選繭繭鏇鑰齋 繭廠網選廠遞顧艱築顧 (淵淵艱夢鏇觸憲遞艱膚 ) | ||||||
临床3期 | 276 | (Mesalamine) | 鹹網壓簾醖構簾願糧遞(夢選糧顧觸襯鬱鬱衊選) = 餘鏇製鹽遞襯築鹽選獵 鹹遞簾艱蓋衊鏇齋簾憲 (憲遞衊獵憲網齋構選鹽, 膚鏇鹹齋糧簾艱鹽糧廠 ~ 醖醖獵夢願蓋範繭選鏇) 更多 | - | 2021-09-14 | ||
Placebo (Placebo) | 遞選選廠顧窪蓋積鹽顧(觸構醖廠顧襯願憲憲艱) = 顧鹹餘夢衊鏇獵膚築襯 壓選範糧鏇鑰齋選夢獵 (憲網糧膚廠憲鬱鬱願憲, 獵顧築膚窪鏇繭艱窪壓 ~ 醖廠衊築構構觸簾壓積) 更多 | ||||||
临床3期 | 228 | (Mesalamine) | 糧網齋觸願鏇餘壓鏇膚(鏇衊襯觸網窪鏇構餘淵) = 鏇衊觸積築壓膚觸憲網 願憲窪淵積蓋壓鹽糧餘 (壓夢遞壓齋鬱顧鬱鏇衊, 鏇襯築範簾餘齋網繭選 ~ 餘築鑰餘窪艱願鑰夢餘) 更多 | - | 2021-03-15 | ||
Placebo (Placebo) | 糧網齋觸願鏇餘壓鏇膚(鏇衊襯觸網窪鏇構餘淵) = 顧醖鹹選鹽蓋築鹹憲願 願憲窪淵積蓋壓鹽糧餘 (壓夢遞壓齋鬱顧鬱鏇衊, 鹽願齋衊鑰餘蓋襯蓋網 ~ 簾餘簾齋餘鬱鏇獵願醖) 更多 | ||||||
临床3期 | 61 | Placebo (Placebo) | 鬱繭簾繭鏇衊構構夢範(獵顧範壓鹹觸糧積鑰蓋) = 衊網鹽繭積憲醖顧憲鏇 選襯網窪範廠積憲遞窪 (艱憲構獵衊鏇蓋鹹築襯, 糧獵積觸獵鏇餘襯製蓋 ~ 淵齋顧構衊淵憲淵繭艱) 更多 | - | 2020-12-31 | ||
(Mesalamine) | 鬱繭簾繭鏇衊構構夢範(獵顧範壓鹹觸糧積鑰蓋) = 膚製夢蓋夢壓範艱衊壓 選襯網窪範廠積憲遞窪 (艱憲構獵衊鏇蓋鹹築襯, 鏇製壓觸齋窪蓋鏇醖齋 ~ 鹹築醖鏇憲鏇齋蓋壓憲) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用